EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study

Luc Biedermann, Christoph Schlag, Alex Straumann, Alfredo J Lucendo, Stephan Miehlke, Michael Vieth, Cecilio Santander, Constanza Ciriza de Los Rios, Christoph Schmöcker, Ahmed Madisch, Petr Hruz, Jamal Hayat und 9 weitere

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2024.10.034 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Luc Biedermann und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. Electronic address: luc.biedermann@usz.ch. Hauptthemen laut MEDLINE: Budesonide, Eosinophilic Esophagitis, Anti-Inflammatory Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Budesonide orodispersible tablets (BOT) have been shown to be safe and effective in phase III double-blind trials of induction and 48-week maintenance therapy of eosinophilic esophagitis (EoE). We now analyzed the long-term efficacy and safety of BOT in a 96-week open-label extension (OLE) study. METHODS: All patients with EoE in the 48-week double-blind maintenance study were eligible to receive BOT treatment for up to 96 weeks. Dosage was 0.5 or 1.0 mg BOT, twice daily, at investigator's discretion. Clinical, histologic, endoscopic, quality of life, and safety measures were assessed. RESULTS: A total of 186 patients participated in the OLE up to 96 weeks. At week 96, 81.9% of patients had clinical remission, defined as an EoE Symptom Activity Index (EEsAI) score of ≤20 vs 77.7% at OLE baseline. A further 80.1% of patients were in histologic remission, defined as peak eosinophils per high-power field of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BudesonideEosinophilic EsophagitisAnti-Inflammatory AgentsHumansMaleFemaleAdultTreatment OutcomeTabletsMiddle AgedAdministration, OralYoung AdultDouble-Blind MethodAdolescentQuality of LifeDrug-Related Side Effects and Adverse ReactionsAged

Stichwörter der Autor:innen

Eosinophilic EsophagitisMaintenance TherapyRemissionSafetyTopical Corticosteroid

Substanzen

BudesonideTabletsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. Electronic address: luc.biedermann@usz.ch.
  • Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; Swiss EoE Research Network, Center of Gastroenterology, Olten, Switzerland.
  • Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain;…
  • Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany; Center for Esophageal Diseases, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Klinikum Bayreuth, Bayreuth, Germany.

Zitieren

APA

Biedermann, L., Schlag, C., Straumann, A., Lucendo, A. J., Miehlke, S., Vieth, M., Santander, C., Ciriza de Los Rios, C., Schmöcker, C., Madisch, A., Hruz, P., Hayat, J., von Arnim, U., Bredenoord, A. J., Schubert, S., Halstead, M., Pfurr, S., Mueller, R., Schoepfer, A. M., …, & International EOS-2 Study Group (2025). Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.10.034

Vancouver

Biedermann L, Schlag C, Straumann A, Lucendo AJ, Miehlke S, Vieth M, et al. Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.10.034

BibTeX
@article{Biedermann2025,
  author = {Biedermann, Luc and Schlag, Christoph and Straumann, Alex and Lucendo, Alfredo J and Miehlke, Stephan and Vieth, Michael and Santander, Cecilio and Ciriza de Los Rios, Constanza and Schmöcker, Christoph and Madisch, Ahmed and Hruz, Petr and Hayat, Jamal and von Arnim, Ulrike and Bredenoord, Albert Jan and Schubert, Stefan and Halstead, Mike and Pfurr, Sabrina and Mueller, Ralph and Schoepfer, Alain M and Attwood, Stephen and International EOS-2 Study Group, International EOS-2 Study Group},
  title = {Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2024.10.034}
}
Kostenlos starten →